Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial-Reference-Cited by-同舟云学术

Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial

Published:2006-10 Issue:9544 Volume:368 Page:1329-1338
ISSN:0140-6736
Container-title:The Lancet
language:en
Short-container-title:The Lancet

Author:

Demetri George D,van Oosterom Allan T,Garrett Christopher R,Blackstein Martin E,Shah Manisha H,Verweij Jaap,McArthur Grant,Judson Ian R,Heinrich Michael C,Morgan Jeffrey A,Desai Jayesh,Fletcher Christopher D,George Suzanne,Bello Carlo L,Huang Xin,Baum Charles M,Casali Paolo G

Publisher

Elsevier BV

Subject

General Medicine

Reference38 articles.

1. Gastrointestinal stromal tumors—definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis;Miettinen;Virchows Arch,2001

2. The effect of surgery and grade on outcome of gastrointestinal stromal tumors;Pierie;Arch Surg,2001

3. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival;DeMatteo;Ann Surg,2000

4. Soft tissue leiomyosarcomas and malignant gastrointestinal stromal tumors: differences in clinical outcome and expression of multidrug resistance proteins;Plaat;J Clin Oncol,2000

5. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors;Hirota;Science,1998

Cited by 2265 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Intratumoral microbiome promotes liver metastasis and dampens adjuvant imatinib treatment in gastrointestinal stromal tumor;Cancer Letters;2024-10

2. Anti-tumor effect of antibody-drug conjugate targeting cell adhesion molecule 1 on GIST cells representing small intestinal GIST;Experimental and Molecular Pathology;2024-10

3. Fibroblast Growth Factor 2 (FGF2) Activates Vascular Endothelial Growth Factor (VEGF) Signaling in Gastrointestinal Stromal Tumors (GIST): An Autocrine Mechanism Contributing to Imatinib Mesylate (IM) Resistance;Cancers;2024-09-07

4. The INSIGHT study: a randomized, Phase III study of ripretinib versus sunitinib for advanced gastrointestinal stromal tumor with KIT exon 11 + 17/18 mutations;Future Oncology;2024-09-04

5. Case report: Male genital system, soft tissue and myocardial metastases in a patient with exon 11-mutated GIST of unknown origin;Frontiers in Oncology;2024-09-03